|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk.
|
12376473 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.
|
12482965 |
2003 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.
|
11751884 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
|
18776922 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
|
17376218 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
Therapeutic
|
group |
CTD_human |
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
|
16266977 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.
|
22666205 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
|
15754350 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
|
17141945 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Therapeutic
|
group |
CTD_human |
Endocrine approaches in the therapy of prostate carcinoma.
|
15790600 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Flow cytometric analysis of androgen receptor expression in human prostate tumors and benign tissues.
|
10815917 |
2000 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells.
|
17553795 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines.
|
17055455 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Two thirds of prostate tumors retained high levels of ZNF652 (71/109 cases) and 50% of tumors high levels of AR (57/113).
|
20204290 |
2010 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Endocrine approaches in the therapy of prostate carcinoma.
|
15790600 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
Therapeutic
|
group |
CTD_human |
Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.
|
22666205 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
|
15640154 |
2005 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Because ARA70 can promote the antiandrogen hydroxyflutamide (HF)-enhanced AR transactivation, the increased ARA70 expression in hormone-refractory prostate tumors may confer the development of HF withdrawal syndrome, commonly diagnosed in patients with the later stages of prostate cancer.
|
15166229 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
|
14654929 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
Therapeutic
|
group |
CTD_human |
Androgen deprivation therapy for prostate cancer: current status and future prospects.
|
15389811 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
|
11927493 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
To identify HOXB13 transcriptional targets in metastatic PCs, we performed integrative bioinformatics analysis of differentially expressed genes (DEGs) in the proximity of the human prostate tumor-specific AR binding sites.
|
31273254 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The coregulatory proteins ARA70 and ARA160 differentially affected the activity of the mutated AR Glu(231)-->Gly, which was discovered in a mouse authochthonous prostate tumor.
|
12083956 |
2001 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In the present study we investigated the effects of this antisense AR ODN on prostate tumor growth in vivo using a mouse xenograft model.
|
11857028 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.
|
17906287 |
2008 |